A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

被引：0
|
作者：
Wang, Jianbo
Campbell, Matthew T.
Shah, Amishi Yogesh
Goswami, Sangeeta
Msaouel, Pavlos
Alhalabi, Omar
Hahn, Andrew Warren
Kovitz, Craig A.
Jana, Bagi Rp
Araujo, John C.
Gao, Jianjun
Zurita, Amado J.
Jonasch, Eric
Corn, Paul Gettys
Tannir, Nizar M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS745
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of sunitinib in renal cell cancer with untreated brain metastases.
    Chevreau, C.
    Ravaud, A.
    Escudier, B.
    Caty, A.
    Delva, R.
    Rolland, F.
    Oudard, S.
    Herve, R.
    Blanc, E.
    Ferlay, C.
    Lignon, N.
    Negrier, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Albiges, Laurence
    Burotto, Mauricio
    Szczylik, Cezary
    Zurawski, Bogdan
    Ruiz, Eduardo Yanez
    Maruzzo, Marco
    Zaizar, Alberto Suarez
    Fein, Luis E.
    Schutz, Fabio A.
    Heng, Daniel Y. C.
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    van Kooten Losio, Maximiliano
    Suarez, Cristina
    Motzer, Robert J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19): : 1767 - 1778
  • [3] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Gervaso, Lorenzo
    Fazio, Nicola
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (05): : 476 - 477
  • [4] Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
    McGregor, Bradley Alexander
    Huang, Jiaming
    Xie, Wanling
    Xu, Wenxin
    Bilen, Mehmet Asim
    Braun, David A.
    Zhang, Tian
    McKay, Rana R.
    McDermott, David F.
    Hammers, Hans J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] A PHASE 3 STUDY (COSMIC-313) OF CABOZANTINIB IN COMBINATION WITH NIVOLUMAB AND IPILIMUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA OF INTERMEDIATE OR POOR RISK
    Choueiri, Toni
    Albiges, Laurence
    Powles, Thomas
    Mohamed, Nehal
    Wang, Fong
    Motzer, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A209 - A209
  • [6] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
    Cerrato, Clara
    Pradere, Benjamin
    Mir, Maria Carmen
    EUROPEAN UROLOGY, 2023, 84 (04) : E93 - E93
  • [7] Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell Carcinoma
    Rizzo, Alessandro
    Mollica, Veronica
    Massari, Francesco
    JAMA ONCOLOGY, 2022, 8 (05) : 783 - +
  • [8] A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.
    Choueiri, Toni K.
    Albiges, Laurence
    Powles, Thomas
    Scheffold, Christian
    Wang, Fong
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
    McGregor, B. A.
    Paul, M.
    Xie, W.
    Xu, W.
    Bilen, M. A.
    Braun, D. A.
    Berg, S.
    Zhang, T.
    McKay, R. R.
    McDermott, D. F.
    Hammers, H.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1020 - S1020
  • [10] A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma
    Kato, Renpei
    Kojima, Takahiro
    Sazuka, Tomokazu
    Yamamoto, Hayato
    Fukuda, Shohei
    Yamana, Kazutoshi
    Sugino, Yusuke
    Hamamoto, Shuzo
    Nakaigawa, Noboru
    Kabu, Koki
    Murakami, Hiroshi
    Obara, Wataru
    ANTICANCER RESEARCH, 2021, 41 (12) : 6199 - 6209
12345